Prostate News and Research

RSS

Exposure to arsenic can turn normal stem cells into cancer stem cells

Researchers at the National Institutes of Health have discovered how exposure to arsenic can turn normal stem cells into cancer stem cells and spur tumor growth. Inorganic arsenic, which affects the drinking water of millions of people worldwide, has been previously shown to be a human carcinogen.

4 Apr 2012

Lilly announces results of three preclinical studies that focus on c-MET receptor

Eli Lilly and Company today announced results of three preclinical studies focused on c-MET, a receptor tyrosine kinase that, when it functions normally, plays a key role in transmitting signals within a cell.

3 Apr 2012

Clinical data for cabozantinib to be presented at ASCO annual meeting

Exelixis, Inc. announced today that its lead compound, cabozantinib, will be the subject of nine separate data presentations at the upcoming Annual Meeting of the American Society of Clinical Oncology.

2 Apr 2012

Scientists use DNA sequencing to identify 'driver' mutations in cancer

Scientists at Washington University School of Medicine in St. Louis are using powerful DNA sequencing technology not only to identify mutations at the root of a patient's tumor - considered key to personalizing cancer treatment - but to map the genetic evolution of disease and monitor response to treatment.

2 Apr 2012

WCMC receives SU2C-PCF Prostate Dream Team Translational Cancer Research Grant

An international team of investigators from centers in the United States and the United Kingdom, including Weill Cornell Medical College, have been awarded a grant for $10 million over a three-year period to study the molecular underpinnings of metastatic prostate cancer while creating a comprehensive testing system to optimize personalized treatments.

2 Apr 2012

Galeterone safe, effective for patients with CRPC

Patients with castration-resistant prostate cancer had limited side effects and in many cases a drop in prostate-specific antigen expression with galeterone (TOK-001), a small-molecule oral drug, according to phase I data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

2 Apr 2012

Hypoxia in tumors can predict prostate cancer recurrence in men

Low oxygen levels in tumors can be used to predict cancer recurrence in men with intermediate-risk prostate cancer even before they receive radiation therapy.

2 Apr 2012

Tokai Pharmaceuticals announces data from galeterone Phase 1 trial for CRPC

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that its lead candidate galeterone (TOK-001) was well-tolerated with minimal side effects and demonstrated efficacy in patients with castration-resistant prostate cancer (CRPC) in a Phase 1 study.

2 Apr 2012

Metformin may slow growth rate of prostate cancer in men

The use of metformin in men with prostate cancer before prostatectomy helped to reduce certain metabolic parameters and slow the growth rate of the cancer, according to the results of a phase II study.

2 Apr 2012

FDA won’t ban bisphenol A from food packaging

In a long drawn decision the U.S. government announced Friday that it will not ban bisphenol A, an industrial chemical believed to disrupt the reproductive and nervous systems, from food and drink packaging.

1 Apr 2012

New breast cancer gene mutation discovered

A large international study led by University of Melbourne researchers has identified a mutation linked to breast cancer attached to the newly identified gene, called XRCC2. Lead researcher Melissa Southey said the discovery, using high-speed technology, would hopefully mean that more gene mutations responsible for causing breast cancer could be rapidly identified in the next few years.

1 Apr 2012

CT scans more effective than traditional lung cancer detection methods

A new study led by researchers at Mount Sinai School of Medicine indicates that CT scans are more effective than traditional lung cancer detection methods at identifying aggressive lung cancers in their most treatable stages.

31 Mar 2012

Massively parallel sequencing quickly identifies breast cancer risk gene

An international team of researchers led by the University of Melbourne has used new technology to fast track the discovery of a breast cancer risk gene and could assist in the discovery of other cancer genes.

30 Mar 2012

Cancer death rates declining but obesity still needs to be tackled

According to a new report from four major national cancer tracking groups there has been a steady decline in cancer death rates for men, women and children from 2004 to 2008. The declines in death and new cases of cancer reflect progress against the disease in terms of prevention, diagnosis and treatment, but experts say rising obesity may present a new challenge in the fight against cancer.

29 Mar 2012

New treatment approach halts spread of cancer cells into normal brain tissue

Treating invasive brain tumors with a combination of chemotherapy and radiation has improved clinical outcomes, but few patients survive longer than two years after diagnosis. The effectiveness of the treatment is limited by the tumor's aggressive invasion of healthy brain tissue, which restricts chemotherapy access to the cancer cells and complicates surgical removal of the tumor.

29 Mar 2012

Researchers design new treatment approach for invasive brain tumors

Researchers from Emory and the Georgia Institute of Technology have designed a new treatment approach that appears to halt the spread of cancer cells into normal brain tissue in animal models.

29 Mar 2012

MabCure retains CUNY CAT to evaluate monoclonal antibodies against ovarian cancer

MabCure Inc., a leading developer of antibody-based technology for the diagnosis and treatment of ovarian, prostate, colorectal and other cancers, has retained the CUNY Center for Advanced Technology (CUNY CAT) to evaluate its monoclonal antibodies against ovarian cancer cells as diagnostic reagents.

29 Mar 2012

Strand Diagnostics to receive $30 million in funding from NantWorks

Strand Diagnostics, LLC, maker of the know error system, and NantWorks, LLC announced that they have entered into an agreement whereby Strand will receive up to $30 million in funding from NantWorks, LLC over the next 3 years.

29 Mar 2012

Potential new therapy that kills cancer cells selectively

Researchers have made a drug that helps the immune system to break down cancerous tumors. It has worked on breast, bowel, prostate, ovarian, brain, bladder and liver cancers, while previous studies show it can also be used to fight some blood cancers. If given early, the drug could even be a cure, researchers say.

28 Mar 2012

Intermittent androgen suppression therapy for prostate cancer

Androgen suppression - the inhibition of testosterone and other male hormones - is a routine therapy for prostate cancer. Unfortunately, it can dramatically reduce the quality of patients' sex lives and, more importantly, lead to cancer recurrence in a more deadly androgen-independent form.

28 Mar 2012